Get started
Amicus Therapeutics, Inc.Amicus Therapeutics, Inc.Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

FOLD chart


Full chart

FOLD upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.28 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.35 USD
Net income (FY)
‪−151.58 M‬ USD
Revenue (FY)
‪399.36 M‬ USD
Shares float
‪291.19 M‬
Beta (1Y)
0.22

Employees


Employees (FY)
517
Change (1Y)
+33 +6.82%
Revenue / Employee (1Y)
‪772.45 K‬ USD
Net income / Employee (1Y)
‪−293.20 K‬ USD

About Amicus Therapeutics, Inc.


Sector
Health Technology
CEO
Bradley Lewis Campbell
Headquarters
Princeton
Website
amicusrx.com
Founded
2002
FIGI
BBG000PLF6N0
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

FOLD news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of FOLD is 10.99 USD — it has increased by 0.09% in the past 24 hours. Watch Amicus Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Amicus Therapeutics, Inc. stocks are traded under the ticker FOLD.
FOLD stock has fallen by −3.77% compared to the previous week, the month change is a 9.57% rise, over the last year Amicus Therapeutics, Inc. has showed a −3.26% decrease.
We've gathered analysts' opinions on Amicus Therapeutics, Inc. future price: according to them, FOLD price has a max estimate of 21.00 USD and a min estimate of 14.00 USD. Watch FOLD chart and read a more detailed Amicus Therapeutics, Inc. stock forecast: see what analysts think of Amicus Therapeutics, Inc. and suggest that you do with its stocks.
FOLD reached its all-time high on Dec 22, 2020 with the price of 25.39 USD, and its all-time low was 1.77 USD and was reached on Apr 16, 2014. View more price dynamics on FOLD chart.
See other stocks reaching their highest and lowest prices.
FOLD stock is 3.84% volatile and has beta coefficient of 0.22. Track Amicus Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Amicus Therapeutics, Inc. there?
Today Amicus Therapeutics, Inc. has the market capitalization of ‪3.28 B‬, it has decreased by −1.53% over the last week.
Yes, you can track Amicus Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Amicus Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
FOLD earnings for the last quarter are −0.02 USD per share, whereas the estimation was 0.00 USD resulting in a ‪−1.79 K‬% surprise. The estimated earnings for the next quarter are 0.02 USD per share. See more details about Amicus Therapeutics, Inc. earnings.
Amicus Therapeutics, Inc. revenue for the last quarter amounts to ‪141.52 M‬ USD, despite the estimated figure of ‪134.93 M‬ USD. In the next quarter, revenue is expected to reach ‪146.97 M‬ USD.
FOLD net income for the last quarter is ‪−6.73 M‬ USD, while the quarter before that showed ‪−15.70 M‬ USD of net income which accounts for 57.13% change. Track more Amicus Therapeutics, Inc. financial stats to get the full picture.
No, FOLD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 11, 2024, the company has 517.00 employees. See our rating of the largest employees — is Amicus Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Amicus Therapeutics, Inc. EBITDA is ‪23.09 M‬ USD, and current EBITDA margin is −16.43%. See more stats in Amicus Therapeutics, Inc. financial statements.
Like other stocks, FOLD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Amicus Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Amicus Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Amicus Therapeutics, Inc. stock shows the sell signal. See more of Amicus Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.